The discovery of a novel target can result in exceptionally successful classes of anticancer drugs. For example, the combined global sales in 2024 of PD1–PDL1 inhibitors — for which the first-in-class ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback